The SEAVUE study is the first head-to-head trial that compares the safety and efficacy of prescription biologics in the treatment of Crohn's disease, and results were presented during the 2021 Digestive Disease Week virtual meeting.
In this second of four exclusive roundtable episodes, MedPage Today brought together three leaders in the field -- moderator Jason K. Hou, MD, of Baylor College of Medicine in Houston, is joined by Shirley Cohen-Mekelburg, MD, of Michigan Medicine in Ann Arbor, and Jill Gaidos, MD, of Yale School of Medicine in New Haven, Connecticut -- for a virtual roundtable discussion about how the SEAVUE (Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year) trial results might impact their practice.
